Abstract
Immunocompromised children with acute leukemias and solid tumors are at high risk of fatal varicella infection. Reviewing a total of 242 patients at risk we have found that zoster immune plasma from reconvalescent patients (ZIP) and commercially available specific varicella/zoster immune globulin (VZIG) both prevent fatal disease. In addition, Acyclovir was effective against VZV-infections in this group of patients. We summarize our present policy of prophylaxis and treatment of immunocompromised children with neoplastic disease who have been exposed to VZV.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
